Clinical Trials Logo

Filter by:
NCT ID: NCT06323031 Not yet recruiting - Clinical trials for Disorders of Consciousness

Spontaneous Eye Blinking in Disorders of Consciousness

Blink-DoC
Start date: May 2024
Phase:
Study type: Observational

Differential diagnosis between Unresponsive Wakefulness Syndrome (UWS) and Minimally Conscious State (MCS) is complicated due to severe cognitive and/or sensorimotor deficits in these patients. In this study the investigators aimed at exploring the diagnostic and prognostic validity of spontaneous eye blinking parameters (rate, amplitude, duration, variability) in a sample of patients with Disorders of Consciousness (DoC). This is a multi-center prospective observational study conducted in patients with Severe Acquired Brain Injury (sABI) and DoC admitted to 8 European participating centers, with clinical data collection not deviating from routine practice. The study is non-commercial and will have a maximum total duration of 24 months.

NCT ID: NCT06321991 Recruiting - Dupuytren's Disease Clinical Trials

Nodular Shrinking in Dupuytren Disease

Echo
Start date: February 15, 2024
Phase: Phase 2
Study type: Interventional

Dupuytren disease (DD) is a common hand disorder with disabling finger contractures that may require surgery to restore function. In the early stages of the disease, the nodules (Tubiana stage 0) are usually painless, but a reason for concern to many patients. Not rarely, lifestyle measures and even risky treatment options as radiotherapy are advised, yet no therapy to prevent disease evolution has a solid proven effect. Furthermore, reliable non-invasive measurement of early stage DD is not validated. Evidence was found that pharmacotherapy may influence DD evolution, but valuable clinical trials are limited. Case series and non-published explorative follow-up suggested local treatment with antioxidant vitamin E to possibly interfere with an evolution of DD nodules to contracting strands. This study aims to provide evidence on efficiency of this non-invasive treatment option. Secure measurement of nodule evolution is a clinical challenge. To measure this evolution, ultrasound and MRI scanning are currently being performed. Stage 0 (nodules) is more challenging to quantify. A strict individual follow-up by the treating clinician is needed to standardize measurement of selected (treated) nodules. Therefore, simple ultrasound by the treating clinician may provide an good tool to collect data. This study aims to introduce and validate this non-invasive scan method and provide a prospective double blind investigation of a measurable effect of non-invasive preventive treatment for stage 0 DD to improve clinical outcome.

NCT ID: NCT06321874 Completed - Abdominal Cancer Clinical Trials

Effects of Oxygen After Abdominal Oncological Surgery

EPHIRAS
Start date: January 1, 2011
Phase: N/A
Study type: Interventional

The aims of the research is to determine whether a Hyperoxic intermittent stimuli protocol can increase reticulocyte counts, signififying a rise in EPO production, in patients undergoing abdominal surgery

NCT ID: NCT06321562 Recruiting - Clinical trials for Primary Open-angle Glaucoma

Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma

Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma and pseudophakia. The main questions it aims to answer are how safe the investigational drug is and how the body tolerates it. The study will also check: - how safely the implant is placed in and removed from the eye and how the body responds to the procedure, - how safe different doses of timolol are and how the body handles taking it, - the amount of Timolol released in the bloodstream, - if there is any positive effect on the pressure inside the eye.

NCT ID: NCT06317818 Recruiting - Safety Issues Clinical Trials

Is Local Injection of Mesenchymal Stem Cells After Endoscopic Dilation Safe and Does it Improve the Outcome of Intestinal Stricture in Patients With Crohn's Disease?

Start date: June 6, 2023
Phase: Phase 2
Study type: Interventional

This is an exploratory phase II study, to evaluate the impact of these Mesenchymal Stem Cells (MSCs) on strictures in Crohn's disease patients with symptomatic intestinal stricture eligible to endoscopic dilatation. The impact of combined treatment by endoscopic dilation and local injection of MSCs will be compared with that of a control group.

NCT ID: NCT06317090 Completed - Clinical trials for Alveolar Bone Resorption

Vertical GBR LPRF Block vs. Autogenous Bone With DBBM

Start date: July 2, 2018
Phase: N/A
Study type: Interventional

split-mouth RCT, 25 months follow up. GBR protocol with LPRF as grafting material in the test group and autogenous bone with DBBM as grafting material in the control group.

NCT ID: NCT06311110 Active, not recruiting - Clinical trials for Lower Urinary Tract Symptoms

Impaired Toilet Training, LUTS and Bowel Dysfunction in Children With DCD

Start date: October 30, 2023
Phase:
Study type: Observational

This cross-sectional case-control study aimed to determine whether there is a significant difference in the prevalence of impaired toilet training, LUTS, and functional bowel problems among children diagnosed with DCD and typically developing children (TDC).

NCT ID: NCT06310356 Not yet recruiting - Clinical trials for Gestational Diabetes

Continuous Glucose Monitoring for Women With Gestational Diabetes

CORDELIA
Start date: September 2024
Phase: N/A
Study type: Interventional

There are a few ongoing large randomized controlled trials (RCT's) on continuous glucose monitoring (CGM) in women with gestational diabetes (GDM) powered for pregnancy outcomes. However, none of these studies included women diagnosed with early GDM. The CORDELIA trial is a Belgian open-label multi-centric RCT with 14 centers in women with GDM (including both early and late GDM). Women will be randomized 1/1 to either treatment with CGM (intervention group, Freestyle Libre 3) or continue with self-monitoring of blood glucose (SMBG) with glucometer in line with normal routine (control arm). The study ends at the postpartum oral glucose tolerance test (OGTT 6-24 weeks postpartum) to screen for glucose intolerance.

NCT ID: NCT06308965 Not yet recruiting - Clinical trials for Arthroplasty Complications

Does Vessel-sparing Surgery in Anterior Approach Total Hip Arthroplasty Change Clinical Outcome?

USP
Start date: March 2024
Phase: N/A
Study type: Interventional

During direct anterior approach (DAA) for total hip arthroplasty (THA), ligation of the lateral femoral circumflex artery and vessel is always conducted. However, this standardized procedure may jeopardize blood muscle perfusion and cause tenderness in the tensor fascia lata muscle. The investigators want to investigate whether blood vessel-sparing surgery is feasible, reproducible, and would alter outcomes following DAA THA. The surgical technique of the vessel-sparing procedure will be described and investigated in a prospective blinded RCT. The investigators hypothesize that the vessel-sparing technique is feasible in 60% of the patients. If these vessels were not sacrificed, the investigators expect the incidence of TFL tendinopathy to be lower.

NCT ID: NCT06308029 Recruiting - Breast Cancer Clinical Trials

Effectiveness of an eHealth Self-management Support Program for Persistent Pain After Breast Cancer Treatment

PECAN
Start date: April 12, 2024
Phase: N/A
Study type: Interventional

The scientific goals of the project are: 1. The primary scientific objective of the study is to determine the effectiveness of an eHealth self-management support program for persistent pain after breast cancer treatment compared to: - usual care (i.e. superiority of the eHealth self-management support program) and - a comprehensive pain rehabilitation program delivered face-to-face in a physical therapy setting (i.e. non-inferiority of the eHealth self-management support program) on pain-related disability (measured with the Pain Disability Index). 2. The secondary scientific objectives of this study entails to examine if the eHealth self-management support program has a relative benefit for other biopsychosocial factors, including: - Other dimensions of pain - Health-related quality of life - Physical functioning, including physical activity levels - Psychosocial functioning, including self-efficacy, stress, anxiety, depression, coping style (key secondary outcome) and fear of cancer recurrence - Participation in society, including return to work - Healthcare-related costs for the patient and society 3. The tertiary scientific objectives of this study are - to identify moderators of treatment effect, including behavioural determinants (e.g. self-efficacy, motivation, coping style), in order to identify breast cancer survivors who would benefit the most of the eHealth self-management support program and to allow more stratified and efficient pain management care and more targeted allocation of budgets. - To examine the implementation process, mechanisms of impact and contextual factors.